Health Canada has released Natural Health Product Licensing Bulletin No.11 introducing a significant operational change to the way Finished Product Specifications (FPS) are handled for Natural Health Product (NHP) product licence applications (PLAs).
Effective June 25, 2026, applicants filing Class II and Class III NHP applications will no longer be expected to submit Finished Product Specifications (FPS) as part of their product licence or amendment submissions.
At first glance, the bulletin may appear to reduce quality requirements for NHPs. In practice, however, very little changes from a compliance or GMP standpoint.
The core obligation to establish, maintain, validate, and follow compliant FPS remains fully in force under the Natural Health Products Regulations (NHPR) and Health Canada’s updated Good Manufacturing Practices (GMP) framework.
This update is best understood as an administrative streamlining measure — not a relaxation of product quality expectations.
Historically, companies submitting Class II and III NHP applications were expected to provide Finished Product Specifications directly as part of the PLA package.
Under the previous framework, FPS documentation formed part of Health Canada’s product review process and any changes to specifications that widened tolerances or materially altered testing methodologies could require amendments to the product licence.
Class I applications already operated differently, where FPS did not need to be routinely submitted but still had to be maintained and provided upon request.
Health Canada has now extended this approach to all NHP application classes.
According to the bulletin, the intent is to reduce administrative burden while maintaining a risk-based oversight model appropriate to the level of product risk.
Health Canada specifically notes that FPS requests during application review may still occur for products presenting elevated quality or risk considerations, including cannabis-containing NHPs and other higher-risk submissions.
Importantly, this operational bulletin does not eliminate or reduce GMP obligations tied to specifications, testing, quality systems, or product release activities.
While the bulletin removes the expectation that Finished Product Specifications (FPS) be submitted with Class II and III applications, it does not remove the obligation to establish and maintain compliant FPS.
Health Canada explicitly states that regulated parties must continue to:
The bulletin also confirms that this process change does not alter any Good Manufacturing Practices (GMP) requirements.
As a result, companies should not interpret this announcement as a reduction in quality obligations. The primary change is that Health Canada will no longer routinely review FPS as part of the licensing process unless quality or risk concerns warrant additional scrutiny.
This bulletin appears to be part of Health Canada’s broader movement toward:
Rather than reviewing FPS routinely during every application, Health Canada is increasingly shifting responsibility onto regulated parties to maintain compliant systems internally and produce supporting documentation only when required.
That does not reduce liability. If anything, the modernized GMP framework and evolving enforcement environment place greater emphasis on companies maintaining robust internal quality systems capable of standing up to inspection and enforcement scrutiny.
As discussed previously in our article, “Health Canada Finalizes New Good Manufacturing Practices (GMP) Guide for Natural Health Products (NHPs),” the updated GMP framework represents far more than a simple modernization exercise.
The finalized Version 4 GMP Guide introduced:
Taken together, these updates represent a significant shift in how Health Canada intends to assess compliance across the NHP sector.
Health Canada has indicated that future amendments to the Natural Health Products Regulations will take this operational change into consideration.
Since the Regulations currently require that a specification be submitted as part of a product licence application and that certain changes to specifications be filed as amendments, it remains to be seen how Health Canada will reconcile this latest bulletin with existing regulatory requirements.
For now, the bulletin represents Health Canada’s current administrative approach to FPS submissions and FPS-only amendments. Companies should continue to monitor regulatory developments and seek regulatory advice if they are uncertain how the bulletin applies to their specific circumstances.
From a practical standpoint, Health Canada is no longer requesting routine submission of FPS with Class II and III applications and has indicated that FPS-only changes no longer require notification or amendment filings. However, organizations remain responsible for establishing, maintaining, and providing compliant FPS upon request, while ensuring their quality systems continue to meet all applicable GMP requirements.
Some companies may incorrectly interpret this bulletin as meaning FPS are now less important. That would be a significant compliance mistake.
Under the updated GMP framework:
This becomes particularly important during:
The cost associated with GMP non-compliance, inspection findings, import disruptions, recalls, or enforcement action vastly outweighs the relatively trivial cost associated with properly preparing and maintaining FPS documentation.
Under Vanessa’s Law and Health Canada’s increasingly modernized enforcement approach, organizations should not assume gaps in documentation or quality systems will go unnoticed.
The finalized GMP framework represents a substantial operational shift for many NHP companies — particularly those managing complex supply chains, importer obligations, or expanding quality systems.
To help organizations prepare, dicentra offers updated Inspection-Ready NHP GMP Training developed by regulatory and quality experts actively supporting companies through:
The training reflects how GMP expectations are applied in practice — not just how they are written — and includes practical guidance on:
The program is designed for:
In addition to GMP training, dicentra supports NHP companies with:
If your organization is preparing NHP submissions, reviewing its GMP systems, or looking to train internal teams on the updated Health Canada GMP framework, contact dicentra to discuss your compliance strategy and training needs.